Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perillyl alcohol intranasal - NEONC Technologies

Next Previous
X
Search
Drug Profile

Perillyl alcohol intranasal - NEONC Technologies

Alternative Names: NEO 100; Perillyl-alcohol-intranasal-NEONC-Technologies; POH

Latest Information Update: 17 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NEONC Technologies
  • Developer National Cancer Institute (USA); NEONC Technologies
  • Class Monoterpenes; Small molecules
  • Mechanism of Action Apoptosis stimulants; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Meningioma
  • Phase I/II Glioma
  • No development reported Glioblastoma
  • Discontinued Cancer

Most Recent Events

  • 12 Apr 2024 Neonc Technologies plans a phase I trial for Brain cancer (In Adolescents, In children, Recurrent) (Intranasal), in May 2024 (NCT06357377)
  • 10 Apr 2024 Pharmacokinetics data from a preclinical trial in Glioblastoma were presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 01 Jul 2022 Phase-II clinical trials in Meningioma (Recurrent, Metastatic disease, Second-line therapy or greater) in USA (Intranasal) (NCT05023018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top